Kam joins Tetraphase with a track record of over two decades of financial leadership in the life sciences and consumer goods industries. Most recently, Kam spent over 11 years overseeing finance organizations at Thermo Fisher Scientific, a global leader in serving science. Across her multiple roles at Thermo Fisher, she led financial operations, corporate financial planning and analysis, and finance for business strategy. During her tenure there, Kam led finance for the customer channels group, the chemical analysis division, and businesses with revenues that ranged from
"We are delighted to welcome Kam at this exciting time for the Company," said Guy Macdonald, President and Chief Executive Officer of Tetraphase. "Kam's strong financial leadership experience and strategic business insight will be a valuable addition to the executive team at Tetraphase, particularly as we continue to build the infrastructure to support the commercialization of eravacycline, our lead antibiotic candidate."
"I am thrilled to join Tetraphase, a company committed to bringing innovative medicines to patients to address the growing public health crisis of antibiotic resistance," said
Kam holds a master of science in administration from
Inducement Equity Awards
Additionally, Tetraphase's Compensation Committee of the Board of Directors approved, pursuant to Rule 5635(c)(4) of the Nasdaq Global Select Market, options to
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "anticipates," "believes," "expects," "plans," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether the results of the Company's development efforts will warrant regulatory submission and whether any such submissions will receive approval from the
News Provided by Acquire Media